{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:39:19Z","timestamp":1789105159376,"version":"build-2803163510"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The relationships between antituberculosis drug exposure and treatment effects on humans receiving multidrug therapy are complex and nonlinear. In patients on treatment, an analysis of the rate of decline in the sputum bacillary burden reveals two slopes. The first is the \u03b1-slope, which is thought to reflect bactericidal effect, followed by a \u03b2-slope, which is thought to reflect sterilizing activity. We sought to characterize the effects of standard first-line treatment on sterilizing activity. Fifty-four patients receiving combination therapy for pulmonary tuberculosis in a clinical trial had drug concentrations measured and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Mycobacterium tuberculosis<\/jats:named-content>\n            isolates available for MIC identification. Sputum sample cultures were performed at baseline and weekly for 8 weeks. A time-to-event model based on the days to positivity in the liquid cultures was used to estimate the \u03b2-slope. The pharmacokinetic parameters of rifampin, isoniazid, ethambutol, and pyrazinamide were determined for each patient. Multivariate adaptive regression splines analyses, which simultaneously perform linear and nonlinear analyses, were used to identify the relationships between the predictors and the \u03b2-slope. The potential predictors examined included HIV status, lung cavitation, 24-h area under the concentration-time curve (AUC), peak drug concentration (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ), AUC\/MIC ratio,\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            \/MIC ratio, and the time that that concentration persisted above MIC. A rifampin\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            of &gt;8.2 mg\/liter and a pyrazinamide AUC\/MIC of &gt;11.3 were key predictors of the \u03b2-slope and interacted positively to increase the \u03b2-slope. In patients with a rifampin AUC of &lt;35.4 mg \u00b7 h\/liter, an increase in the pyrazinamide AUC\/MIC and\/or ethambutol\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            \/MIC increased the \u03b2-slope, while increasing isoniazid\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            decreased it, suggesting isoniazid antagonism. Antibiotic concentrations and MICs interact in a nonlinear fashion as the main drivers of a sterilizing effect. The results suggest that faster speeds of sterilizing effect might be achieved by omitting isoniazid and by increasing rifampin, pyrazinamide, and ethambutol exposures. However, isoniazid and ethambutol exposures may only be of importance when rifampin exposure is low. These findings need confirmation in larger studies. (This study has been registered at\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/controlled-trials.com\">controlled-trials.com<\/jats:ext-link>\n            under registration no. ISRCTN80852505.)\n          <\/jats:p>","DOI":"10.1128\/aac.03931-14","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T03:23:42Z","timestamp":1413257022000},"page":"38-45","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":127,"title":["Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis"],"prefix":"10.1128","volume":"59","author":[{"given":"Emmanuel","family":"Chigutsa","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jotam G.","family":"Pasipanodya","sequence":"additional","affiliation":[{"name":"Office of Global Health, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne E.","family":"Visser","sequence":"additional","affiliation":[{"name":"School of Public Health, University of the Western Cape, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"van Helden","sequence":"additional","affiliation":[{"name":"DST\/NRF Centre of Excellence for Biomedical TB Research\/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Sirgel","sequence":"additional","affiliation":[{"name":"DST\/NRF Centre of Excellence for Biomedical TB Research\/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"Office of Global Health, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200210-1125OC"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.6.2062-2069.1996"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.167.4.603"},{"key":"e_1_3_3_5_2","first-page":"295","article-title":"Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid","volume":"82","author":"Canetti G","year":"1960","unstructured":"Canetti G, Grumbach F, Grosset J. 1960. Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid. Am Rev Respir Dis 82:295\u2013313.","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.5.1223"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.123.3.445"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.123.3.469"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(85)90040-6"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.03.007"},{"key":"e_1_3_3_11_2","first-page":"128","article-title":"A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"12","author":"Rustomjee R","year":"2008","unstructured":"Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA, Gatifloxacin for TB (OFLOTUB) Study Team. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12:128\u2013138.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_12_2","first-page":"792","article-title":"Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting","volume":"12","author":"Pheiffer C","year":"2008","unstructured":"Pheiffer C, Carroll NM, Beyers N, Donald P, Duncan K, Uys P, van Helden P. 2008. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis 12:792\u2013798.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01876-12"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01533-06"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01681-08"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00414-06"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/599040"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/429321"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"e_1_3_3_21_2","first-page":"247","article-title":"Nonlinear systems in medicine","volume":"75","author":"Higgins JP","year":"2002","unstructured":"Higgins JP. 2002. Nonlinear systems in medicine. Yale J Biol Med 75:247\u2013260.","journal-title":"Yale J Biol Med"},{"key":"e_1_3_3_22_2","volume-title":"MARS user guide","author":"Salford Systems","year":"2001","unstructured":"Salford Systems. 2001. MARS user guide. Salford Systems, San Diego, CA."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.5754\/hge10155"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573406411309080005"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10038-008-0313-z"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2292"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.110.001784"},{"key":"e_1_3_3_28_2","volume-title":"WHO\/CDS\/TB\/2003.313","author":"WHO","year":"2003","unstructured":"WHO. 2003. Treatment of tuberculosis: guidelines for national programmes, 3rd ed. WHO\/CDS\/TB\/2003.313. World Health Organization, Geneva, Switzerland. http:\/\/whqlibdoc.who.int\/HQ\/2003\/WHO_CDS_TB_2003.313_eng.pdf.","edition":"3"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01833-10"},{"key":"e_1_3_3_30_2","volume-title":"Population Approach Group Europe (PAGE)","author":"Chigutsa E","year":"2010","unstructured":"Chigutsa E, McIlleron H, Holford N. 2010. Parallel first order and mixed order elimination of pyrazinamide in South African patients with tuberculosis, abstr. 1946. Population Approach Group Europe (PAGE), 8 to 11 June 2010, Berlin, Germany."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03940.x"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00274-11"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02501-08"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176347963"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-09"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.7.1002"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.03.022"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00830-09"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.3.548"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00269-11"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8284673"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/79558"},{"key":"e_1_3_3_43_2","volume-title":"Conference on Retroviruses and Opportunistic infections (CROI)","author":"Sloan DJ","year":"2014","unstructured":"Sloan DJ, Schipani A, Waterhouse D, Stone L, Mwandumba HC, Butterworth AE, Heyderman RS, Corbett EL, Khoo S, Davies G. 2014. Pharmacokinetic variability in TB therapy: associations with HIV and effect on outcome, abstr 106. Conference on Retroviruses and Opportunistic infections (CROI), 3 to 6 March 2014, Boston, MA."},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-951OC"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262150-00001"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku136"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/147.4.958"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-210"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03931-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03931-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:57:13Z","timestamp":1645484233000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03931-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1128\/AAC.03931-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03931-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"2014-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}